Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO

1. Sanofi, a global biopharmaceutical company, is focusing on Chronic Obstructive Pulmonary Disease (COPD) as the "next major growth pillar" for its immunology drug Dupixent, according to its CEO Paul Hudson.

2. Dupixent, a monoclonal antibody, is currently approved for treating conditions like moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

3. The company is conducting clinical trials to explore Dupixent's potential in treating COPD, a progressive lung disease that makes it hard to breathe.

4. If successful, this expansion into COPD treatment could significantly boost Dupixent's sales and further establish Sanofi's position in the immunology market.

5. The drug has already shown promising results in treating other conditions, and Sanofi hopes to replicate this success in COPD treatment.

6. The CEO's statement reflects Sanofi's strategic approach to leverage its existing products for new indications, thereby driving growth and innovation.